Statins and CPAP in Adipose Tissue of OSA (SCAT-OSA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03308578|
Recruitment Status : Enrolling by invitation
First Posted : October 12, 2017
Last Update Posted : January 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Sleep Apnea, Obstructive||Drug: Atorvastatin Drug: Placebo oral capsule||Phase 1 Phase 2|
In recent years the role adipose tissue to the development of cardiometabolic disorders has been increasingly recognized. Dysfunctional adipose tissue is an important source for systemic inflammation and FFA, thus increasing CV risk in obese and aging populations. Even though heightened cardiovascular risk in OSA patients is acknowledged, adipose tissue from OSA patients has not been investigated.
CPAP is standard therapy for OSA, but has shown mixed results for improvement of vascular function, insulin sensitivity, and BP, and does not reduce CV events and mortality, even in patients with established CV disease. Hence, eliminating IH alone may not be sufficient to repair preexisting damage; additional adjunct strategies aimed at cellular repair may be required to reduce cardiometabolic burden and CV risk. Statins have pleiotropic effects including reducing inflammation, and improving BP. The aim of this study is to examine the longitudinal changes in the cellular and molecular composition of adipose tissue in OSA subjects in response to 6 months combination therapy of CPAP and atorvastatin. We hypothesize that the combination therapy will reduce adipose tissue cellular damage (p16INK4A+γ-H2AX dual positive cells). Also, decreases in adipose tissue cellular damage will be associated with improved cardiometabolic profile. These studies will provide pivotal insights into potential therapeutic strategies which may reduce cardiometabolic burden in OSA population.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||Statins and CPAP in Adipose Tissue: A Randomized Clinical Trial in Obstructive Sleep Apnea|
|Actual Study Start Date :||January 8, 2018|
|Estimated Primary Completion Date :||October 1, 2022|
|Estimated Study Completion Date :||July 2023|
Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
Placebo Comparator: Placebo Oral Capsule
Subjects randomized to this arm will receive placebo capsules matching study drug.
Drug: Placebo oral capsule
Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
- Changes in prevalence of dual positive p16IND4A and gamma H2AX cells in adipose tissue [ Time Frame: Approximately 6 months ]Positivity for both (p16^IND4A and γH2AX) serves as a marker of cellular damage. Fat biopsy from the will be performed to obtain up to 1 gm of adipose tissue. These fat samples will be batched for analysis to determine the prevalence of cellular damage. Biopsy will be obtained at 3 months and 6 month follow-up.
- Changes in prevalence of phosphorylated p53 (pp53) in adipose tissue [ Time Frame: approximately 6months ]Presence of pp53 as a ratio of phospho to total p53 to access cellular damage in adipose tissue at 3 month and 6 month follow-up
- Changes in 24- h mean arterial pressure [ Time Frame: approximately 6months ]Changes in ambulatory measure of blood pressure at 3 month and 6 month.
- Changes in vascular endothelial function [ Time Frame: approximately 6months ]Comparison of change in brachial artery diameter in response to hyperemia at 3 month and 6 month follow-up.
- Changes in insulin sensitivity [ Time Frame: approximately 6months ]Changes in the measure for area under the curve for glucose and insulin as determined during oral glucose tolerance test at 3 month and 6 month.
- Changes in body composition [ Time Frame: approximately 6months ]Changes in percentage body fat content at 3 month and 6 month.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03308578
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Virend Somers, MD, PhD||Mayo Clinic|
|Principal Investigator:||Prachi Singh, Ph.D.||Mayo Clinic|